Rofecoxib (Vioxx) should have been withdrawn from the market 4 years
ago because there was sufficient evidence at that time that the drug raised
the risk of myocardial infarction, a team of researchers from Switzerland
and the United Kingdom concluded in a November 5 online edition of the Lancet (http://www.thelancet.com). Merck &
Co Inc, the drug’s manufacturer, had announced on September 29 that
it was withdrawing the drug, a selective cyclooxygenase 2 (COX-2) inhibitor,
from the market.
Stephenson J. Vioxx Controversy. JAMA. 2004;292(23):2827. doi:10.1001/jama.292.23.2827-a